GlassScriptPhysician profile
Russell J Tanner
NPI 1871544486
$1,051.32
in general payments reported to CMS, 2019-2025
25 companies · $301 in 2025
The $301 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $232 · 2022: $136 · 2023: $212 · 2024: $171 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $645 · Education: $39.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.52 |
| Education | $39.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bardy Diagnostics, INC. | $100.00 | 2021 | |
| Lilly USA, LLC | $87.71 | 2021-2025 | Mounjaro, Zepbound |
| Echosens North America, INC. | $86.65 | 2025 | Fibroscan |
| Novo Nordisk INC | $73.53 | 2023-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $72.76 | 2023 | Xarelto, Spravato |
| Corcept Therapeutics | $69.27 | 2022 | |
| Antares Pharma, INC. | $64.20 | 2024-2025 | Xyosted |
| Abbott Laboratories | $57.12 | 2021-2023 | Gallant |
| Amgen INC. | $47.97 | 2023-2025 | Otezla, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $39.24 | 2023-2024 | |
| Dexcom, INC. | $36.08 | 2022-2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.57 | 2021-2022 | |
| Inspire Medical Systems, INC. | $32.81 | 2023-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $31.31 | 2025 | Airsupra |
| Gilead Sciences, INC. | $30.47 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $27.27 | 2025 | Symbravo |
| Pfizer INC. | $23.18 | 2024 | |
| Astellas Pharma US INC | $23.09 | 2023 | Myrbetriq |
| Abbvie INC. | $20.44 | 2021 | |
| Glaxosmithkline, LLC. | $20.09 | 2024 | Trelegy Ellipta, Arexvy |
| Optinose US, INC. | $17.86 | 2024 | |
| Genentech USA, INC. | $16.94 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.99 | 2025 | Caplyta |
| Halozyme INC | $13.74 | 2023 | |
| Philips North America LLC | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.